- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05356351
An Open-label, Single-arm, Multicenter Phase II Clinical Study: Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer
April 29, 2022 updated by: Tianjin Medical University Cancer Institute and Hospital
An Open-label, Single-arm, Multicenter Phase II Clinical Study: Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer.It's arm to evaluate the neoadjuvant treatment of Her2-positive Muscle-invasive Bladder Cancer in patients with objective response rate (ORR),Duration of response (DoR) , progression-free survival (PFS), overall survival (OS), and safety.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
Objective response rate (ORR), Duration of response (DoR) (according to RECIST 1.1 Standard Edition),progression-free survival (PFS), overall survival (OS), quality of life (QoL)and safety.
Evaluation once every 2 weeks before cystectomy, If the efficacy results of the evaluation are complete response (CR) or partial response (PR), confirmed imaging efficacy at 9 weeks after the initial assessment , efficacy evaluation time window of ± 14 days.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subject is volunteer to participate, and the subject must signed an informed consent form (ICF), indicating that it understands the purpose of this study and the required procedures, and is willing to participate in the study. Subjects must be willing and abide by prohibition and restrictions specified in the research program; Subjects are willing and able to follow the trial and follow-up procedures
- Patients with invasive bladder cancer are prepared for radical cystectomy (standard lymph node dissection);
- Age ≥ 18 years old and ≤ 75 years old;
- Clinical stage T2-T4aN0M0 (assessed by CT/MR/PET-CT);
- Pathological was confirmed urothelial carcinoma by TURBT, HER2 overexpression confirmed by pathological biopsy: IHC2+ or IHC3+(central laboratory verification) andthe physical condition was not suitable for neoadjuvant chemotherapy ( pathological permit urothelial carcinoma Combined with other variant subtypes, with urothelial carcinoma as the main type) or refused neoadjuvant chemotherapy;
- ECOG score ≤ 1;
- After TURBT, residual tumor (measurable according to RECIST 1.1 criteria) is present;
The important laboratory examination indexes meet the following requirements:
- Hemoglobin ≥ 90g/L.
- Absolute neutrophil count (ANC) ≥ 1.5 × 109 / L.
- Platelet ≥ 100 × 109 / L.
- 3.5mmol/L ≤ serum potassium ≤ 5.5mmol/L.
- Liver function index: ALT, AST ≤ 1.5 times the upper limit of normal value (ULN), TBIL ≤ 1.5ULN.
- Subjects with Serum creatinine≤ 1.5× ULN
- The left ventricular ejection fraction (LVEF) was 50%.
- Female subjects should be surgically sterilized or postmenopausal, or agree to use at least one medically approved contraceptive method (such as intrauterine device, contraceptive or condom) during the study treatment and within 6 months after the end of the study treatment period. The blood pregnancy test must be negative within 7 days before the study, and it must be non-lactation. Male subjects should agree to use at least one medically approved contraceptive method (such as condoms, abstinence, etc.) during the study treatment period and within 6 months after the end of the study treatment period.
Exclusion Criteria:
- Had received live attenuated vaccine or had serious infection or planned to receive any vaccine during the study period4 weeks before entering the group.
- Received antineoplastic therapy within 6 months before the start of the study, including chemotherapy, radiotherapy, targeted therapy, immunotherapy and clinical research antineoplastic drug therapy.
- Uncontrollable concomitant diseases, including, but not limited to, persistent infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, arrhythmia, interstitial lung disease, severe chronic gastrointestinal disease associated with diarrhoea, or mental illness / social conditions, which will limit compliance with research requirements, significantly increase the risk of AE or impair the patient's ability to write informed consent.The results of HIVAb test were positive;with active bleeding or new thrombotic disease who are taking therapeutic anticoagulants or who have a tendency to bleed
- Patients with RC48-ADC /PD-1 allergy or hypersensitivity, patients with autoimmune diseases;
- HBsAg or HBcAb test results are positive, while HBVDNA copies are positive; HCVAb test results are positive (only if the PCR test result of HCVRNA is negative);Systemic corticosteroids or other systemic immunosuppressive drugs are used before enrollment, or systemic immunosuppressive drugs are expected to be needed during the trial;
- Serious arteriovenous thrombosis or cardio-cerebrovascular accidents occurred within 1 year before administration, such as deep venous thrombosis, pulmonary embolism, cerebral infarction, cerebral hemorrhage, myocardial infarction, etc., except for lacunar infarction that is asymptomatic and does not require clinical intervention;with active bleeding or new thrombotic disease who are taking therapeutic anticoagulants or who have a tendency to bleed.
- Active/known/suspected autoimmune disease, history of primary immunodeficiency,Previous allogeneic hematopoietic stem cell transplantation;
- Diagnosed with other malignancies within 5 years
- Pregnant or lactating women.
- Patients with missing main observation indicators, incomplete research data, incomplete follow-up data or failure to follow the research protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: test group
RC48-ADC 2.0 mg/kg)D1,Triplizumab 3mg/kg D2,Q2W
|
RC48-ADC 2.0 mg/kg D1,Triplizumab 3mg/kg D2,Q2W
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological response (PaR) rate
Time Frame: Up to approximately 6 months
|
Pathological response (PaR) rate per central pathology review
|
Up to approximately 6 months
|
recommended dose for phase II safety (RP2D)
Time Frame: Up to approximately 6 months
|
tolerability
|
Up to approximately 6 months
|
Incidence of adverse events and serious adverse events
Time Frame: Up to approximately 6 months
|
safety
|
Up to approximately 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The pathological complete response
Time Frame: Up to approximately 6 months
|
The pathological complete response rate refers to all target lesions disappear
|
Up to approximately 6 months
|
Progression free survival
Time Frame: Up to approximately 24 months
|
Follow-up was made after the first month after the operation, and then with an every three months until the tumor relapsed or progress
|
Up to approximately 24 months
|
Overall survival
Time Frame: Up to approximately 48 months
|
The time from start of study treatment to date of death due to any cause
|
Up to approximately 48 months
|
Duration of response
Time Frame: Up to approximately 24 months
|
This is the time from when the tumor begins to respond to treatment until the disease gets worse
|
Up to approximately 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 1, 2022
Primary Completion (Anticipated)
July 1, 2023
Study Completion (Anticipated)
July 30, 2027
Study Registration Dates
First Submitted
April 18, 2022
First Submitted That Met QC Criteria
April 29, 2022
First Posted (Actual)
May 2, 2022
Study Record Updates
Last Update Posted (Actual)
May 2, 2022
Last Update Submitted That Met QC Criteria
April 29, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC48-TA001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Sharing Supporting Information Type
- Study Protocol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
-
Guangdong Provincial People's HospitalNot yet recruitingNeoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
-
RenJi HospitalBeiGene; RemeGen Co., Ltd.RecruitingHER2 | Non-Muscle Invasive Bladder CancerChina
-
Institut Claudius RegaudCepheidUnknownNon Muscle Invasive Bladder Cancer | Treatment by BCGFrance
-
Pusan National University Yangsan HospitalRecruitingUrothelial Carcinoma | Neoadjuvant Chemotherapy | Muscle Invasive Bladder CancerKorea, Republic of
-
Ain Shams UniversityCompletedUrinary Bladder Cancer | BCG | Urinary Bladder Neoplasm | Non-Muscle Invasive Bladder Urothelial Carcinoma | Trans Urethral Resection of a Bladder TumorEgypt
-
IRCCS San RaffaeleRecruitingBladder Cancer | Bladder Disease | Bladder Cancer Recurrent | Bladder Urothelial Carcinoma | Non Muscle Invasive Bladder Cancer | Bladder Neoplasm | Non-Muscle Invasive Bladder Urothelial Carcinoma | Non-Muscle Invasive Bladder Neoplasms | Bladder Cancer Stage I, With Cancer in Situ | Bladder Urothelial... and other conditionsItaly
-
Tianjin Medical University Second HospitalRecruitingHer2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaChina
-
PrecirixActive, not recruitingAdvanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care TreatmentUnited States, Canada
-
University of WashingtonPatient-Centered Outcomes Research InstituteActive, not recruitingBladder Cancer | Non-muscle Invasive Bladder Cancer | Cancer of the Bladder, RecurrentUnited States
-
RenJi HospitalRecruitingRadiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug ConjugatesChina
Clinical Trials on RC48- ADC
-
Cancer Institute and Hospital, Chinese Academy...RecruitingMetastatic Breast CancerChina
-
RemeGen Co., Ltd.Completed
-
RemeGen Co., Ltd.Completed
-
RemeGen Co., Ltd.RecruitingMuscle Invasive Bladder CarcinomaChina
-
Chinese PLA General HospitalRecruitingAdvanced Gastroesophageal AdenocarcinomaChina
-
Peking Union Medical College HospitalRecruitingSalivary Gland TumorsChina
-
RemeGen Co., Ltd.Completed
-
RemeGen Co., Ltd.Not yet recruitingNon-small Cell Lung CancerChina